

Pierre Close M.Sc., PhD



Pierre Close M.Sc., PhD

PROFESSOR

Molecular Biology Specialist

Principal Investigator of National Fund for Scientific Research (FNRS), head of the Laboratory of Cancer Signaling Group of Applied Genoproteomics (GIGA) and professor of the University of Liège (ULg). He has had a great interest in new mechanisms promoting tumor adaptation to identify novel therapeutic strategies in the treatment of invasive or resistant human cancers. He has many international scientific publications in high impact factor journals such as: Nature, Cell, Oncogene, Journal of Biological Chemistry among others.

Full name: Pierre Close

Country: Belgium

Current Position:

- 2017-present WELBIO Principal Investigator (Walloon Excellence in Life Sciences and Biotechnology).
- 2016- present Titular: Thematic seminar (20h), Faculty of Medicine, Biomedical Sciences. University of Liege. Belgium.
- 2014-present Overview in Signaling pathways and networks (3h). University of Liege. Belgium.
- 2014-present Alteration in Signaling pathways in cancer (3h). University of Liege. Belgium.
- 2014-present Cancer stem cells: new challenges for anti-cancer therapy (3h). University of Liege. Belgium.
- 2013-present Principal Investigator (FNRS), Head of the Laboratory of Cancer Signaling GIGA-Institute. Unit of Molecular Biology of Diseases, University of Liege. Belgium.
- 2012-present FNRS Principal Investigator. Belgium.

Education:

- 2006 PhD in Biomedical and Pharmaceutical Sciences.
Faculty of Medicine/ Medical Chemistry. University of Liege. Belgium
- 2003 Master in Pharmaceutical Sciences. Faculty of Medicine/ Department of Pharmacy. University of Liege. Belgium.

2002 PharmD Degree. Faculty of Medicine/ Department of Pharmacy. University of Liege. Belgium.

Experience:

2009 – 2012 FRS-FNRS Post-doctoral fellow shared between the GIGA-Institute. University of Liege. Belgium and the Cancer Research UK, London Research Institute. London. UK.

2006 – 2009 EMBO Post-doctoral fellow in Dr J. Svejstrup Lab. Mechanisms of Gene transcription. Clare Hall Laboratories. London Research Institute. Cancer Research. UK– now the Francis CRICK Institute. UK.

2006 – 2008 EMBO Long-Term post-doctoral fellowship.

2002 – 2006 FNRS PhD fellowship (National Foundation for Scientific Research). Belgium.

2001 – 2002 Teaching Assistant - Laboratory for Drug Analysis of Professor Jacques Crommen. Institute of Pharmacy. University of Liege. Belgium.

1999 – 2000 Teaching Assistant - Laboratory of Professor Guy Dandrifosse. Center of Immunology. Institute of Pathology. University of Liege. Belgium.

Scientific publications

Number of publications as author or co-author: 26

Books chapter: 1

Recent scientific publications:

Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, Sin O, Shostak, Schmitz S, Piepers J, Ghesquière B, Karim L, Charloteaux B, Jamart D, Florin A, Lambert C, Rorive A, Jerusalem G, Leucci, E, Dewaele M, Vooijs M, Leidel SA, Georges M, Voz M, Peers B, Büttner R, Marine JC, Chariot A and Close P. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature, 2018, in press.

Rapino F, Delaunay S, Zhou Z, Chariot A and Close P. tRNA modification: Is cancer having a wobble? Trends in Cancer, 2017, 294-296 (<http://dx.doi.org/10.1016/j.trecan.2017.02.004>). IF: TBD

Delaunay S, Rapino F, Tharun L, Zhou Z, Heukamp LC, Termathe M, Shostak K, Klevernic I, Florin A, Desmecht H, Desmet CJ, Nguyen L, Leidel SA, Willis A, Buttner R, Chariot A and Close P. Eip3 links tRNA modifications to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. The Journal of Experimental Medicine. 2016 Oct 17;213(11):2503-2523. IF: 12.5

Ladang A, Rapino F, Heukamp LC, Tharun L, Shostak K, Hermand D, Delaunay S, Klevernic I, Jiang Z, Jacques N, Jamart D, Migeot V, Florin A, Göktuna S, Malgrange B, Sansom OJ, Nguyen L, Büttner R, Close P, Chariot A. (CLOSE P

and CHARIOT A equally contributed to this work and shared last-authorship; Ladang and Rapino are co-first authors). Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine. *The Journal of Experimental Medicine*. 2015 Nov 16;212(12):2057-75. IF: 12.5